Between the failure of its late-stage cancer drug bintrafusp alfa in a key clinical trial and an unexpected inspection delay for another oncology hopeful, dostarlimab, GlaxoSmithKline is having a bad week,…

Novo Nordisk and Eli Lilly are locked in a tough fight, both vying for the top spot in the GLP-1 diabetes treatment class. On strategy they’ve both pursued is increasing…

Americans are back on the COVID-19 vaccine bandwagon. Sixty-nine percent now plan to get a COVID-19 vaccine, close to the previous high of 73% in April, according to the latest data…

Thanks to dosing logistics, COVID-19 antibodies from Eli Lilly and Regeneron have gotten off to a slow start in the U.S., and now they’re facing a new stumbling block in viral variants. While the…

Limited supplies, spotty logistics and now a deluge. After contending with plenty of other problems, the  U.K.’s coronavirus vaccine rollout faced yet another threat Wednesday night when a Wockhardt plant faced rising…